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The Tousled-like kinases regulate genome and epigenome stability: implications in 
development and disease 
 
Summary 
The Tousled-like kinases (TLKs) are an evolutionarily conserved family of serine-threonine 
kinases that have been implicated in DNA replication, DNA repair, transcription, chromatin 
structure, viral latency, cell cycle checkpoint control and chromosomal stability in various 
organisms. The functions of the TLKs appear to depend largely on their ability to regulate the 
H3/H4 histone chaperone ASF1, although numerous TLK substrates have been proposed. 
Over the last few years, a clearer picture of TLK function has emerged through the 
identification of new partners, the definition of specific roles in development and the 
elucidation of their structural and biochemical properties. In addition, the TLKs have been 
clearly linked to human disease; both TLK1 and TLK2 are frequently amplified in human 
cancers and TLK2 mutations have been identified in patients with neurodevelopmental 
disorders characterized by intellectual disability (ID), autism spectrum disorder (ASD) and 
microcephaly. A better understanding of the substrates, regulation and diverse roles of the 
TLKs is needed to understand their functions in neurodevelopment and determine if they are 
viable targets for cancer therapy. In this review, we will summarize current knowledge of 
TLK biology and its potential implications in development and disease. 
 
Overview of the Tousled-like kinases 
Identification of the Tousled kinase and Tousled-like kinases 
The Tousled (TSL) kinase and Tousled-like kinases (TLKs) belong to a distinct branch of 
nuclear Ser–Thr kinases that are absent in yeast but appear to be constitutively expressed in 
most cells and tissues from plants and animals. TSL was first identified in Arabidopsis 
thaliana where mutations in the single TSL gene led to pleiotropic defects in morphogenesis, 
including delays in flowering time and leaf development [1]. Subsequent analysis of TSL 
showed that its deficiency led to cell cycle abnormalities but its mRNA and protein 
expression levels were stable throughout the cell cycle [2]. Apart from defects in plant 
development that could result from proliferation defects [1], A. thaliana TSL was reported to 
directly affect transcriptional gene silencing. Loss of TSL resulted in reduced H3K9me2, 
associated with heterochromatin, at reactivated gene loci, while no changes were observed in 
the mitosis-associated phosphorylation of histone H3 on Serine-10 (H3S10) [3]. Additionally, 
TSL mutants were hypersensitive to UV-B radiation and methyl methanesulfonate (MMS) 
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and exhibited compromised siRNA-mediated silencing, indicating that TSL loss may lead to 
transcriptional deregulation and impaired DNA damage repair [4,3]. 
 
Following the identification of TSL in A. thaliana, Tousled-like kinases (TLKs) were 
identified in numerous organisms (Figure 1A). This included Trypanosoma brucei, which 
encodes 2 distinct TLKs, as well as, Drosophila melanogaster and Caenorhabditis elegans 
that, like A. thaliana, encode a single TLK gene. The consequences of TLK depletion have 
been analyzed during development in each case, further implicating TLK activity in DNA 
repair, DNA replication, transcription and mitosis [5-8]. At the organismal level, the TLK-1 
gene in C. elegans and Tlk gene in D. melanogaster are essential for viability, as their loss in 
rapidly dividing cells during early development led to severe chromatin abnormalities, 
proliferation defects and lethality [5,7]. In C. elegans, the major defects identified were 
transcriptional, reflected by reduced phosphorylation of RNA polymerase II and histone H3 
Ser10, a marker of mitosis [5,6]. In D. melanogaster, Tlk mutation caused early arrest during 
embryonic development. This is likely due in part to defective chromatin maintenance, as the 
deleterious effects in eye development observed following expression of a kinase-dead TLK 
mutant could be rescued by the overexpression of the histone H3–H4 chaperone ASF1, now 
the most clearly defined substrate of the TLKs [7,9,10]. Apart from being required for 
proliferation during development, Tlk was also identified in a D. melanogaster RNAi screen 
for cell migration, identifying a requirement for TLK in JAK/STAT activation and the 
motility of polar cells [11]. 
 
Like trypanosomes, mammals encode 2 TLK genes, TLK1 and TLK2, located in different 
chromosomes (in humans 2q31.1 and 17q23.2, respectively). TLK1 and TLK2 share 84% 
identity at the amino acid (aa) level and 96% identity in the kinase domain (Figure 1B) [12-
16]. Each gene is reported to encode several isoforms of unknown relevance and an 
additional translationally regulated form of TLK1, termed TLK1B, has been characterized 
[17]. Consistent with data from other organisms, existing evidence suggests important roles 
for mammalian TLK1 and TLK2 in DNA replication, DNA repair, transcription and 
organismal development (proposed roles of TLKs in DNA repair were recently reviewed in 
[18] and will be further summarized here). 
 
Domain organization and structural features of the TLKs 
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Both TLK1 and TLK2 exhibit the highest levels of activity during S-phase and are regulated 
by cell cycle checkpoint signaling in response to DNA damage [2,12,9,19,20]. Both TSL and 
TLKs have a C-terminal protein kinase catalytic domain and a large N-terminal regulatory 
domain defined by putative coiled coil (CC) domains (Figure 1B) [12,1]. Analysis of the A. 
thaliana TSL protein sequence first revealed the predicted CC regions, as well as three 
consensus nuclear localization signal (NLS) sequences in the N-terminus and in vitro assays 
showed that the CC regions of the TSL protein were required for oligomerization and full 
kinase activity [1].  
 
The first X-ray crystal structure of a TLK family kinase domain was recently solved in 
complex with ATPγS, providing insight into the mode of TLK2 activation and a tool for 
modeling small molecule inhibitors [21]. In vitro analysis of TLK2 activity, as well as the 
identification of key autophosphorylation sites critical for its activity, indicated that TLK2 is 
activated through cis-autophosphorylation events in the kinase domain (Figure 1C). These 
autophosphorylation events trigger a conformational change allowing the trans- and cis-
phosphorylation of sites in the N-terminal CC domains and C-tail, similar to what has been 
described for members of the closely related AGC kinase family, and suggesting that TLKs 
do not require an activating phosphorylation like members of the CDK family [21,22]. 
Biochemical studies indicated that monomeric TLK2 cannot achieve full activation and its 
dimerization and subsequent oligomerization are crucial for maximal activity (Figure 1C). 
Activated TLK2 dimers led to the appearance of higher order oligomers, which are dependent 
on autophosphorylation in the loops joining the CC domains. Thus, oligomerization may not 
only trigger activation but also enzymatic activity by means of recruiting additional TLK2 
molecules. It is worth noting that oligomeric constructs are capable of phosphorylating the 
substrate ASF1a while the kinase domain alone, lacking the N-terminal CC containing 
segment, cannot [21]. Thus, it is anticipated that either the CC region or its role in 
dimer/oligomerization are required for substrate recognition. 
 
Most of the autophosphorylation sites identified in TLK2 are found in the loops joining the 
CC domains, suggesting that they are potentially important regulatory domains in vivo [21]. 
Numerous phosphorylation sites have been identified in the extreme N-terminus of TLK1 and 
TLK2, which was removed to promote solubility in the structural and biochemical study of 
the human TLK2 protein [21,23]. This N-terminal region also contains the NLS according to 
sequence analysis and consistent with the N-terminal mutants lacking the first 160 aa failing 
 5 
to localize to the nucleus [21,24]. Whether the N-terminal phosphorylation sites represent 
autophosphorylation or sites of regulation by other kinases remains to be determined. Many 
additional autophosphorylation sites were identified in the extreme C-terminus of TLK2, 
downstream of the kinase domain. These included sites analogous to those in TLK1 that were 
found to be negative regulatory sites targeted for phosphorylation by CHK1 in response to 
DNA damage [19,20,23]. 
 
TLK1 and TLK2 can homo and heterodimerize and this is critically dependent on the first 
coiled-coil (CC1) domain [21]. Therefore, apart from homodimerization within TLK2 
molecules, heterodimerization with TLK1 appears to represent an additional layer of 
regulation (Figure 1C). Whether the substrate selectivity, activity or regulatory inputs of TLK 
homodimers and heterodimers differ will be an important question to resolve in future 
studies. 
 
Interactors and substrates of the Tousled-like kinases 
The histone H3/H4 chaperone ASF1 has been identified as an interactor of TLKs in all 
organisms where it has been examined. In yeast and C. elegans, the C-terminus of ASF1 is 
highly acidic, possibly favoring its interaction with histones (Figure 2). In D. melanogaster 
and mammalian homologs, the C-terminus is instead rich in Ser and Thr residues, which are 
phosphorylated by the Tousled-like kinases (TLKs) or the DNA-dependent protein kinase 
(DNA-PKcs) (Figure 2) [9,10,25]. Thus, it is possible that the phosphorylation of the C-
terminal tail of human ASF1 might provide the functional equivalent of the acidic C-terminal 
tail of yeast ASF1.  
 
TLK-dependent phosphorylation sites in mammalian ASF1a and ASF1b have been mapped 
and functionally investigated (Figure 2). ASF1a is phosphorylated by TLKs during DNA 
replication on its C-terminal tail residues S166, S175, S192 and S199, while ASF1b is 
modified on residues S169 and S198 [10]. Although the precise mechanisms by which ASF1 
is regulated remain unclear, in D. melanogaster, TLK phosphorylation of ASF1 controls its 
stability, while in vertebrates, TLK1-mediated phosphorylation of several sites on the C-
terminal tail of ASF1 promote its binding affinity for the histone H3/H4 heterodimer [10,26]. 
These data suggested that TLK-mediated phosphorylation of ASF1a and ASF1b may 
promote histone delivery to downstream histone chaperones, such as CAF1 and HIRA, for 
replication-coupled and replication-independent chromatin assembly, respectively (Figure 3) 
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[27]. This is further supported by the observation that the de novo deposition of both H3.1 
and H3.3 was impaired by TLK depletion [28]. 
 
Beyond ASF1, few well-validated substrates of TLKs have been described, although the 
proposed substrate spectrum of TLK1 consists of more than 150 proteins [29]. TLK1 has 
been shown to phosphorylate RAD9, a component of the RAD9–RAD1–HUS1 (9-1-1) 
alternative clamp loader that regulates DNA damage-induced CHK1 activation (Figure 3) 
[30-35]. Consistent with the TLKs being transiently inhibited by the checkpoint, a DNA 
damage-induced loss of phosphorylation was observed in RAD9 at S328 [33] and a mild 
reduction in RAD9 pS328 was reported following Bleomycin treatment of TLK1/2-depleted 
cells [25]. The interaction between TLK1 and RAD9 and its phosphorylation on T355 was 
enhanced by DNA damage and implicated in the checkpoint response, and S328 
phosphorylation of RAD9 has been shown to regulate its subcellular localization [30,35]. Our 
own analysis of TLK2 using quantitative IP-mass spectrometry and BioID, as well as other 
approaches, failed to detect RAD9 as a TLK2 interactor, potentially due to differences in 
experimental conditions or specificity with TLK1 [36,29]. Future proteomic experiments 
following acute stress will be needed to fully understand the influence of TLKs on RAD9 and 
the details of the interaction in vivo. 
 
The phosphorylation of H3S10 is required for chromosome condensation and is a widely 
used marker of mitosis [37]. TLKs have been proposed to mediate H3S10 phosphorylation in 
various organisms. In human cells, TLK1B phosphorylated H3S10 in vitro and TLK1B was 
capable of complementing a yeast mutant strain lacking the major yeast H3 kinase, Aurora 
B/IPL1 [13]. In C. elegans, TLK-1 promoted the Aurora B-mediated phosphorylation of 
H3S10 in a kinase independent manner, indicating that the influence on H3S10 is likely an 
indirect effect (Figure 3) [6]. Tlk mutants in D. melanogaster displayed reduced levels of 
phosphorylated histone H3 [7], potentially the result of fewer cells entering mitosis, an effect 
that has also been observed in human cell lines and trypanosomes [7,28,8]. Therefore, while 
TLK depletion clearly influences cell cycle progression, it remains unclear whether H3S10 is 
a direct target of TLK activity in vivo.  
 
Using biotinylated TLK1B in a protein array, 164 putative TLK1B interactors, including the 
NEK1 kinase, which has been implicated in DNA repair, Amyotrophic Lateral Sclerosis 
(ALS) and ciliogenesis, were identified [29,38,39]. The interaction with NEK1 was enhanced 
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following DNA damage and TLK1B phosphorylated NEK1 on T141 (Figure 3). 
Overexpression of a NEK1 T141A mutant influenced cell cycle checkpoint regulation in 
response to damage[29]. Given that NEK1 activity has been linked to ATR activation, these 
results may represent further regulatory integration into the checkpoint response [40].  
 
One of the most consistent interactors we and others have identified, aside from ASF1, is 
LC8-type 1 and 2 (DYNLL1 and DYNLL2) which were originally identified as components 
of the axonemal dynein motor protein complex [41,36,42,43]. LC8 associates with multiple 
interaction partners independently of its motor protein functions, including the kinase NEK9 
and proteins involved in double-strand break (DSB) repair, such as the MRE11-RAD50-
NBS1 complex (MRN), ATMIN/ASCIZ and 53BP1 [44,41,45-47]. LC8 has been proposed 
to play a general role as a multimerization hub that organizes or stabilizes different protein 
complexes (Figure 3) [41]. The TLK2 binding domain for LC8 either lies within the CC1 
domain or it requires heterodimerization with TLK1, as its binding is lost in CC1 deletion 
mutants of TLK2 that have impaired TLK1 interactions [21]. However, LC8 does not appear 
to be a TLK substrate in vitro, as purified LC8 is not phosphorylated by active TLK2 [36]. 
Whether loss of the LC8 interaction impairs other TLK2 interactions or modifies its activity 
in vivo will be interesting to determine, given that phosphorylation of ASF1a by the TLK2-
ΔCC1 mutant is reduced in vitro and LC8 is implicated in the regulation of the NEK9 kinase 
that is also regulated via dimerization [21,48].  
 
Another interactor of TLKs identified through unbiased proteomic analysis is the 
heterochromatin-associated protein RIF1 (Figure 3) [36]. RIF1 was first identified in yeast as 
a regulator of telomere length [49] while in mammals, RIF1 does not have a telomere specific 
role but has been implicated in the control of DNA repair and the regulation of replication 
timing, the latter being a conserved function across species [50-52]. Immunoprecipitation-
mass spectrometry (IP-MS) analysis of ASF1a in human MCF-7 cells revealed extensive 
coverage of both TLK1/2 and RIF1, suggesting the RIF1-TLK interaction may occur through 
ASF1a [53]. Interestingly, both TLK1 and TLK2, but not ASF1a, were identified in RIF1-
associated complexes from IP-MS experiments in mouse ES cells [54]. As RIF1 acts in part 
through the recruitment of the PP1 phosphatase, it is tempting to speculate that it may act as a 
direct TLK regulator but further experiments are needed to address this possibility. 
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Finally, TLKs have been identified as proximal interactors of several key DNA replication 
and repair factors. While this does not indicate that they are necessarily direct interactors, it 
provides some insight into the cellular environment of the TLKs and is consistent with the 
proposition that despite being mostly nuclear soluble proteins they also localize to the 
vicinity of replication factories [10].  TLK1 and TLK2 were identified in a proteomics screen 
performed using BioID-PCNA in synchronized S-phase cells, but not in asynchronous cells, 
regardless of DNA damaging treatments [55]. Moreover, TLK1, TLK2, RIF1 and ASF1a 
were identified as proximal interactors of 53BP1 using APEX2 labeling, whereas TLK2 was 
identified as a proximal interactor of the DNA damage response factor MDC1, which also 
interacts with ASF1a [56,57]. 
 
Organismal and cellular functions of TLK activity 
Roles of the TLKs in mammalian development 
The characterization of TLK1 and TLK2 knockout cells and mice suggested that TLK1 and 
TLK2 play largely redundant roles in genome maintenance [36] consistent with the fact that 
they form heterocomplexes [9,58]. Despite the fact that both kinases appear to be largely 
redundant in homeostatic somatic tissues, Tlk2-deficient mice perished during late 
embryogenesis due to placental failure, while no placental defects were observed in the 
absence of TLK1 [36]. Reduced ASF1 phosphorylation and impaired expression of placental 
markers were observed in Tlk2-deficient placental tissue. The observation that the knockout 
of ASF1a in mice leads to lethality by E9.5 [59], notably earlier than that observed with 
TLK2 deletion, is consistent with the incomplete effect of TLK2 loss on ASF1 
phosphorylation we observed [36]. As mRNA levels of Tlk1 and Tlk2 in the placenta were 
similar but relative TLK1 protein levels were strongly reduced in placenta compared with 
embryonic tissue, it is possible that a translational or post-translational mechanism regulates 
TLK1 protein levels in this tissue. While several E3 ubiquitin ligases have been identified as 
TLK1 and TLK2 interactors, additional work is needed to validate these interactions and 
define their potential roles in post-translational regulation of TLKs in different tissues [60-
62].  
 
Bypass of placental development allowed the generation of Tlk2 null animals that did not 
show any overt phenotypes in homeostatic conditions, similar to Tlk1 null mice [36]. While 
mice appeared anatomically normal, the conditional knockout of Tlk1 and Tlk2 in stromal 
fibroblasts caused increased mammary gland branching and epithelial hyperproliferation 
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[63]. Available data does not rule out specific functions for TLK1 or TLK2 in the context of 
particular cell types or in response to stress and suggests that they can largely compensate for 
each other. Moreover, neither gene acts as a strong tumor suppressor, despite their 
implication in DNA repair and genome instability. The conditional mouse models will no 
doubt play an important role in interrogating potential tissue and cell type specific roles of 
TLK1 and TLK2 in future work. 
 
TLK activity is required for genome and epigenome stability 
Human TLK expression is constitutive at both the mRNA and protein levels throughout the 
cell cycle, similar to what had been observed for TSL. However, TLK1/2 protein kinase 
activity oscillates during the cell cycle, peaking in S-phase [12]. Inhibition of DNA 
replication with numerous agents inhibited TLK kinase activity in a DNA damage response 
(DDR)-dependent manner, indicating that TLK activity is linked to ongoing DNA replication 
and regulated by the checkpoint [12,19,20]. TLK activity has been consistently implicated in 
the maintenance of genome stability across species but exactly how and why TLK activity is 
integrated into the DDR and how it promotes genome integrity remains to be fully elucidated.  
 
In yeast, ASF1 interacts directly with and is a substrate of the checkpoint kinase Rad53 and 
this interaction has been implicated in genome stability and cell cycle checkpoint recovery 
[64,65]. In human cells, ASF1 does not appear to interact directly with the checkpoint 
kinases, but is instead regulated by them indirectly through the TLKs.  CHK1 phosphorylates 
TLK1 at the C-terminal S695 residue, reversibly inhibiting its activity [19,20]. This CHK1-
dependent modulation of TLK1 potentially coordinates global ASF1 histone-binding capacity 
with the checkpoint response and allows chromatin restructuring during DNA repair. The 
attenuation of TLK1 activity upon checkpoint activation is transient and TLK1 was identified 
again as a direct CHK1 target using an analog sensitive CHK1 allele, although the physical 
interaction of CHK1 with TLK1B or TLK2 has not been observed in proteomics studies 
[36,29,66]. This may reflect the fact that most studies have been performed in asynchronous 
cells in the absence of DNA damage or that the interaction is too transient to be detected by 
the methods used. Although similar phosphorylated sites exist in the C-terminus of TLK2, it 
remains unclear if TLK2 is directly regulated by CHK1 or through heterodimerization with 
C-terminally phosphorylated TLK1. 
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Multiple lines of evidence have implicated TLK activity in the control of cell cycle 
progression, both in asynchronous cells and cells with DNA damage. The previously 
described interaction of TLK1 with RAD9, that has multiple roles in the response to DNA 
damage, has been linked to G2/M checkpoint recovery [30,32,33], although other reports 
implicated TLK2, but not TLK1, in G2/M checkpoint recovery through ASF1a-mediated 
transcriptional regulation [67] (Figure 3). Conversely, TLK2 overexpression was also shown 
to impair the DNA damage-induced G2/M checkpoint in human cancer cells and Tlk 
overexpression prolonged G2 in D. melanogaster independently of its activity [68,69]. These 
may explain the observation that overexpression of TLK1B in mouse cells confers enhanced 
resistance to ionizing radiation, that is more toxic in highly proliferative cells [13]. Thus, the 
regulation of TLK levels and activity is required for normal cell cycle progression, likely 
involving numerous interactions and kinase-dependent and independent functions. 
 
In addition to cell cycle progression, TLK activity has been implicated in chromosome 
segregation. The overexpression of a dominant negative form of TLK1B caused chromosome 
missegregation in mouse cells [70] and TLK1 was proposed to regulate myosin II regulatory 
light chain (MRLC) during mitosis to maintain correct chromosome segregation [71]. 
Further, mitotic defects have been observed in worms, flies and trypanosomes, although 
whether these are the result of under-replicated DNA, cell cycle progression defects or bona 
fide mitotic roles of TLK activity remains to be determined [8,7,6]. 
 
In cancer cells, depletion of TLK activity impaired nucleosome assembly and led to 
replication-coupled ssDNA accumulation and fork stalling [28], a state known as replication 
stress [72]. DSBs accumulated over time, inducing the DDR and provoking p53 activation 
and G1 arrest. TLK-depleted cells were sensitized to treatment with checkpoint kinase or 
Poly(ADP-ribose) Polymerase (PARP) inhibitors, indicating that ATR/CHK1 and PARP 
activity were crucial to prevent the rapid collapse of forks arrested due to chromatin assembly 
defects [28]. New histones incorporated during DNA replication can be identified by the lack 
of H4K20 methylation (H4K20me0) that acts to signal the recruitment of the TONSL-
MMS22L homologous recombination complex [73]. Long term (72 hours) depletion of 
CAF1 and ASF1 impaired the recruitment of TONSL-MMS22L to DNA double-strand 
breaks [25]. Impaired nucleosome assembly in TLK-deficient cells would be predicted to 
have a similar effect on TONSL-MMS22L recruitment that could sensitize replication forks 
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to collapse due to ATR/CHK1-dependent suppression of new origin firing and RPA 
exhaustion [74].  
 
In addition to its well-established roles in transcription and replication, ASF1a was recently 
shown to regulate DSB repair. ASF1a is phosphorylated in a DNA damage-dependent 
manner by DNA-PKcs at S192, a residue previously identified to be a TLK target, indicating 
that multiple signaling pathways converge on the C-terminal tail of ASF1 (Figure 2) [10,25]. 
This phosphorylation event promotes MMS22L-TONSL chromatin loading and subsequent 
recruitment of the RAD51 recombinase to promote homologous recombination (HR)-
mediated DNA repair. Paradoxically, ASF1a has also been proposed to suppress HR and 
promote non-homologous end-joining (NHEJ), a competing DSB repair pathway, through its 
ability to interact with MDC1 and promote the recruitment of several key factors, including 
the ubiquitin ligases RNF8 and RNF168 [57]. Considering that DNA damage-induced 
checkpoint activation transiently inhibits TLK activity [19] and ASF1a pS192 occurs after 
DNA damage, even in  TLK1/2-depleted cells [25], it seems unlikely that TLK activity plays 
a major regulatory role. Nevertheless, as TLK activity plays an important role in genome 
stability and interacts with RIF1, a key regulator of DNA repair pathway choice, this 
possibility warrants further investigation [75]. 
 
Despite available evidence indicating that ASF1 is the primary TLK target in metazoans [9], 
it is notable that TLK depletion does not simply phenocopy ASF1 loss. Depletion of total 
ASF1 reduced replication fork speed and caused a strong S-phase arrest without causing RPA 
accumulation or DDR checkpoint activation [28,76]. Treatment with the deoxyribonucleotide 
reductase (RNR) inhibitor hydroxyurea (HU), that generates a robust DDR in cycling cells, 
including ssDNA/RPA accumulation and DNA breaks, failed to do so in ASF1-depleted cells 
[76]. These data, as well as the fact that the inhibition of DNA replication in TLK-depleted 
cells ameliorated the levels or replication stress and DNA damage, indicated that ongoing 
DNA replication underlies much of the genomic instability that accumulates in TLK-depleted 
cells, consistent with its peak activity in S-phase [28]. This may reflect that ASF1 has 
additional functions that are independent of TLK regulation, such as its interactions with the 
MCM2-7 helicase and role in histone recycling, and/or that additional TLK substrates 
influence the phenotypes [76,77].  
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In addition to promoting genome stability, several lines of evidence indicate that TLKs play 
an important role in epigenome maintenance [5,3,67]. TLK2 was identified in an siRNA 
screen for proteins required to maintain the silencing of Kaposi’s sarcoma-associated 
herpesvirus (KSHV) and TLK1 depletion also resulted in reactivation of Epstein-Barr virus 
(EBV) [78]. In addition to exogenous viruses, the impaired de novo nucleosome deposition 
we observed in TLK-depleted cells [28] would be predicted to have potential consequences 
for epigenome maintenance that is required for cell identity programs, as well as the silencing 
of non-coding regions, such as endogenous viruses and telomeres, where ASF1 has been 
previously implicated [79,80]. Notably, we observed a strong decrease in H3.3 deposition in 
TLK-depleted cells and this replacement variant of H3 plays a key role in heterochromatin 
formation at telomeres and other transcriptionally silent genomic regions, as well as in 
promoters of developmentally regulated genes [81,82,28,83,84]. 
 
Roles of TLK activity in human disease 
Despite their implication in replication stress, genome and epigenome instability and 
hyperproliferation, all of which play key roles in cancer etiology, both TLK1 and TLK2 are 
often maintained or amplified in human cancers and few recurrent mutations or copy number 
losses have been identified [28,85,86,63]. This pattern is reminiscent to that of ATR, and to a 
lesser extent CHK1, that is required by many cancers to tolerate increased replication stress 
[87]. These and other data have suggested that TLK activity may be a promising target to 
explore in cancer treatment. In addition, recent genetic studies have now implicated TLK2 
mutations in several neurodevelopmental disorders, including intellectual disability (ID) and 
autism spectrum disorder (ASD), often associated with microcephaly [88-90], raising new 
interest in understanding the precise developmental roles of TLK activity.  
 
TLK activity as a therapeutic target in cancer 
In breast cancer, amplification of the 17q23 region, that contains several candidate 
oncogenes, including TLK2, occurs in more than 40% of tumors. In addition, several TLK2 
single nucleotide polymorphisms (SNP) of unknown function, including rs733025 and 
rs2245092, were significantly associated with breast cancer risk and hormone receptor–
positive breast tumors [91,92]. TLK2 was amplified in luminal ER+ breast cancer and was 
found to be hyper-phosphorylated in proteogenomics studies, potentially indicating increased 
activity [93,21,28,94]. TLK2 overexpression also correlated with increased chromosomal 
instability (CIN) in breast cancer [68] and promoted cell invasion and migration, both 
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characteristics associated with metastasis in luminal breast cancer cells [93]. Moreover, a 
therapeutic effect of TLK2 inhibition or depletion was observed in xenograft models of breast 
cancer and glioblastoma [93,63]. 
 
Analysis of TLK1/2 copy number alterations across pan-cancer genomes showed that TLKs 
are more frequently maintained or amplified than lost [28]. In addition, high TLK1 and TLK2 
expression levels correlated with poor prognosis in several cancer cohorts, including cervical 
squamous cell carcinoma and endocervical adenocarcinoma (TCGA-cesc) and uveal 
melanoma (TCGA-uvm). Targeting TLK activity was proposed as a potential therapeutic 
intervention in prostate cancer and shown to enhance the effects of some chemotherapeutic 
agents, including ATR/CHK1 and PARP inhibitors, as well as cisplatin, in different cancer 
types [28,95-97]. How TLK1 or TLK2 expression is misregulated in cancer remains largely 
unclear. Aside from copy number alterations, miR-16 was shown to regulate TLK1 levels in 
oral squamous cell carcinoma and the circadian E3 ligase complex was demonstrated to 
regulate TLK2 stability, suggesting that alterations in these mechanisms could influence TLK 
levels in some types of cancer [98,62]. 
 
In addition to playing direct roles in DNA replication and chromatin maintenance, TLK1 and 
TLK2 were identified as non-cell autonomous modifiers of RAS pathway signaling in worms 
and mice [63]. Conditional depletion of TLK1 or TLK2 in mouse mammary fibroblasts 
caused hyperproliferation of surrounding mammary epithelial cells, indicating that loss of 
TLK activity leads to cellular crosstalk that may be relevant to their role in cancer and as 
therapeutic targets. Further supporting an important role for TLK depletion provoking a 
secretory response, depletion of Tlk in flies influenced cytokine-dependent signaling during 
cell migration and our recent work has demonstrated that TLK depletion leads to the loss of 
heterochromatin maintenance, desilencing of repetitive elements, including ERVs, and the 
activation of an innate immune response that included the secretion of inflammatory 
cytokines [84,11]. 
 
The emerging picture suggests that like ATR-CHK1, some degree of TLK activity is required 
for cancer cell proliferation and preventing the accumulation of toxic levels of replication 
stress. This requirement may be elevated in highly proliferative cancer cells and demand the 
amplification of the TLK-ASF1 pathway to avoid replication stress. Therefore, targeting TLK 
activity could have a therapeutic benefit in cancer and additionally, it could potentially 
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augment novel selective therapies, including cell cycle checkpoint inhibitors, PARP 
inhibitors and DNA damaging agents [28]. Several small molecule TLK inhibitors have been 
reported, although most of these are highly promiscuous or target many non-kinase proteins, 
thus potent specific inhibitors have yet to be identified [21,93,99]. Future work exploiting the 
TLK2 crystal structure as a tool for rational inhibitor design could conceivably identify 
clinically effective agents for use in cancer treatment [21].  
 
TLK2 mutations in neurodevelopmental disorders 
Neurodevelopmental disorders, including ASD and ID, are commonly caused by de novo 
spontaneous or inherited genetic mutations that affect brain development. A meta-analysis of 
data from over two thousand patients identified TLK2 as one of ten new candidate genes for 
ID and other neurodevelopmental disorders, such as ASD and schizophrenia [88]. These 
patients have de novo loss of function mutations (DNM) and exhibit severe clinical features, 
such as facial dysmorphisms and microcephaly. Previous studies had identified DNMs in 
TLK2 in sporadic ASD [100] and schizophrenia [101]. The fact that TLK2 DNM are 
significantly enriched in ASD was also confirmed by an independent study of a Japanese 
cohort [90]. 
 
A subsequent study involving patients from up to 7 countries characterized 38 unrelated 
individuals with two affected mothers with heterozygous variants in the TLK2 gene with a 
distinct neurodevelopmental disorder with a consistent pathological spectrum, including mild 
developmental delay, behavioral disorders, gastro-intestinal problems and facial 
dysmorphisms [89]. Mutations in the TLK2 gene include loss-of-function (LOF) variants (4 
frameshift, 10 nonsense variants and one balanced translocation resulting in a disruption 
between TLK2 exon 2 and 3) and missense variants (9 missense and 12 canonical splice-site 
variants) (Figure 4A). While TLK1 mutations have not been statistically linked to any distinct 
neurodevelopmental disorder, DNMs have been reported in isolated cases of 
neurodevelopmental disorder patients, suggesting that its role in brain development warrants 
further investigation [102,103,88,104]. It is worth noting that both TLK1 and TLK2 (MIM 
number 608438 and 608439 respectively) are significantly intolerant for both missense and 




TLK2 mutations were found in heterozygosity, indicating that the neurodevelopmental 
defects presumably arise due to haploinsufficiency. We have previously speculated that the 
effects of the ID/ASD related TLK2 mutations could reflect placental defects, although we 
have not observed any clear placental phenotypes in Tlk2 heterozygous mice and the 
possibility that TLK1 mutations may underlie similar disorders would argue against this as 
being the sole cause [36,89]. Four previously described TLK2 ID mutations [88] strongly 
reduced kinase activity in vitro [21], suggesting that at least some of the TLK2 missense 
mutations could have a mild dominant negative effect. However, in other cases that involve 
larger truncations that include the CC1 domain involved in dimerization, haploinsufficiency 
more likely accounts for the related pathologies. 
 
The neural progenitor population is particularly sensitive to cell cycle delays and DNA 
damage. Attrition of these cells is one of the major underlying causes of several 
neurodevelopmental disorders, including Seckel Syndrome, which is characterized by short 
stature and microcephaly [105], both of which are observed in a number of patients with 
heterozygous TLK2 mutations [89]. Hypomorphic mutations in both ATR and several MCM 
components of the replicative helicase have been linked to replication stress and placental 
defects, in the latter case associated with inflammatory responses [106,107]. However, 
analysis of Tlk2-deficient murine placentas did not uncover increased DNA damage signaling 
or proliferative defects, although this cannot be ruled out in humans due to major differences 
in placental development and gestation time [36]. 
 
Alternatively, defects in H3.3 deposition could compromise epigenetic maintenance [28]. 
H3.3 is required for H3K9me3 establishment in telomeres and endogenous retroviral 
elements (ERVs), as well as for H3K27me3 establishment at promoters of developmentally 
regulated genes [81-83]. Consistent with this, depletion of TLK1 delayed downregulation of 
pluripotency genes and impaired embryonic stem cell differentiation, suggesting impaired 
histone-mediated regulation of differentiation programs [108]. Numerous mutations in genes 
involved in epigenetic maintenance have been identified in ASD, including ATRX, that plays 
a prominent role in H3.3 deposition in heterochromatin at retrotransposons and telomeres 
[109,81], as well as KDM5B, KDM5C, SETD5, and DNMT3A [110]. Treatment with the 
histone deacetylase inhibitor valproic acid (VPA) led to increased ERV expression, and 
prenatal exposure to VPA has been linked to autism, identifying links between chromatin 
silencing, placental formation and autism [110-112].  
 16 
 
An additional, non-exclusive possibility is that TLK activity regulates microexon splicing. 
Brain-specific microexon splicing defects have been identified as a possible molecular 
mechanism underlying idiopathic ASD, given that a significant fraction of autistic brains 
analyzed by transcriptomic profiling showed misregulation of microexons and reduced levels 
of regulators of neuronal alternative splicing [113,114]. A recent CRISPR-screen identified 
around 200 regulators of neuronal microexon splicing, several of which are often disrupted in 
ASD [115]. TLK2 was identified as a positive regulator of microexon splicing and was 
implicated in the stability of the alternative splicing factor SRRM4, which is required for 
microexon inclusion [115]. In addition to TLK2, the H3.3 chaperone HIRA was also 
identified, suggesting that TLK2 mutations could potentially impact neuronal microexon 
splicing through its role in regulating ASF1a and H3.3 deposition [28]. Although a 
mechanistic link between histone variant usage and microexon splicing has not been reported 
to our knowledge, post-translational modifications of H3.3 and its influence on the 
transcriptional elongation rate have both been implicated in splicing defects [116,117].  
 
In future work, it will therefore be interesting to determine whether TLK2 mutations in 
human patients compromise ERV silencing, impair DNA replication, affect microexon 
splicing or elicit inflammatory responses that have been associated with ASD and other 
neurodevelopmental disorders, as well as placental defects in animal models (Figure 4B) 
[118-120,107,121,122,84].  
 
Conclusions and open questions 
Despite the recent advances in our understanding of TLK structure, function and roles in 
human disease, many open questions remain about its regulation, targets and cell type 
specific roles. While TLK activity is clearly important for genomic stability and regulated by 
the cell cycle checkpoint machinery, why is it important to rapidly inhibit TLK following 
DNA damage? How does reduced TLK activity cause replication stress and how is ssDNA 
generated at forks stalled by reduced TLK activity? Are other TLK substrates aside from 
ASF1 relevant to fork progression? Is TLK activity important in post-mitotic cell 
populations? Structurally, we now have a clearer picture of the kinase domain but many 
questions remain. What is the structure of the CC domains and their polarity in the context of 
TLK dimers or multimers? How do they influence subcellular localization, activity or 
substrate selection? How does the phosphorylation of the C-terminus of TLK1 by CHK1 
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influence activity and does this apply to TLK2? Finally, as it is clear that TLKs are important 
during development and even appear to be selected for in cancer, a detailed analysis of their 
cell type and tissue specific roles will be needed. Is the influence of TLK mutations on 
neurodevelopment cell autonomous and if so, what cell types are affected and how? Would 
targeting TLK activity in cancer represent a viable strategy? Addressing these and other 
questions will further our insight into the important roles of these poorly-understood kinases 
in genome and epigenome maintenance. 
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Figure 1. A. Phylogenetic tree generated by Clustal Omega and domain organization of 
TSL/TLKs across organisms. The total number of residues of each protein is shown. B. 
Domain architecture of human TLKs. C. Schematic of activation mechanism of human TLKs 
based on structural and biochemical studies [21]. 
 
Figure 2. Comparison of yeast ASF1, the 2 C. elegans ASF1 proteins (encoded by the unc-
85 and asfl-1 genes) and human ASF1a and ASF1b proteins. The green boxes show the 
conserved histone chaperone domain of about 70% similarity between human and budding 
 18 
yeast/C. elegans. The red boxes show the acidic region present in both yeast and C. elegans 
ASF1. The phosphosites identified in the C-ter tail of human ASF1a/b are indicated 
[10,25,26]. The total number of residues of each protein is shown. In the right panel, 
sequence identity and similarity between the 1-156 aa of yeast (y), C. elegans (ce) and human 
(h) ASF1 are displayed as a percentage and were assessed by NCBI Blast (blastp suite-
2sequences).  
 
Figure 3. Schematic summary model of the proposed functional roles of TLKs through 
various interactors and substrates involved in genome and epigenome stability. See main text 
for details. 
 
Figure 4. A. Diagram of the TLK2 protein (Q86UE8) mapping all of the human TLK2 
mutations identified in patients with neurodevelopmental disorders, ID or ASD [89,88]. For 
splicing variants, the annotated transcript variant corresponding to Q86UE8-1 
(NM_001284333.1) was used. B. Summary schematic of the possible underlying mechanisms 
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